Axogen, Inc. (AXGN) stock
AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/30142% above fair value
$55.37−0.01 (-0.02%)
Close on Nov 17, 2026Market cap $3.31BP/E –Yield –
Axogen price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Axogen's price to sales ratio was 12.5× on Nov 11, 2026, against 6.2× a year earlier. Over the last 5 years it ranged from 1.1× to 12.5×, with a median of 3.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.5× | +5.5 |
| 2025 | Dec 31, 2025 | 7.0× | +3.0 |
| 2024 | Dec 31, 2024 | 4.0× | +2.1 |
| 2023 | Dec 29, 2023 | 1.9× | −1.2 |
| 2022 | Dec 30, 2022 | 3.1× | +0.1 |
| 2021 | Dec 31, 2021 | 3.0× | −3.6 |
| 2020 | Dec 31, 2020 | 6.7× | −0.3 |
| 2019 | Dec 31, 2019 | 6.9× | −3.3 |
| 2018 | Dec 31, 2018 | 10.2× | −7.0 |
| 2017 | Dec 29, 2017 | 17.2× | +10.0 |
| 2016 | Dec 30, 2016 | 7.2× | +1.1 |
| 2015 | Dec 31, 2015 | 6.1× | +2.0 |
| 2014 | Dec 31, 2014 | 4.2× | −3.6 |
| 2013 | Dec 31, 2013 | 7.8× | +3.5 |
| 2012 | Dec 31, 2012 | 4.3× | −2.6 |
| 2011 | Dec 30, 2011 | 6.9× | – |
See a number that looks wrong?